Смертельно опасные лекарства и организованная преступность

23. Lehman R., Yudkin J. S., Krumholz H. M. Licensing drugs for diabetes. BMJ. 2010; 341: 513–14.

24. Solomon D. H., Winkelmayer W. C. Cardiovascular risk and the thiazolidinediones: déjа vu all over again? JAMA. 2007; 298: 1216–18.

25. Dormandy J. A., Charbonnel B., Eckland D. J., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005; 366: 1279–89.

26. Charbonnel B., Dormandy J., Erdmann E., et al. The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care. 2004; 27: 1647–53.

27. PROactive Study Executive Committee and Data and Safety Monitoring Committee. PROactive study. Lancet. 2006; 367: 982.

28. Gøtzsche P. C., Hrybjartsson A., Johansen H. K., et al. Constraints on publication rights in industryinitiated clinical trials. JAMA. 2006; 295: 1645–6.

29. Chan A.-W., Hrybjartsson A., Haahr M. T., et al. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA. 2004; 291: 2457–65.

30. Chan A.-W., Hrybjartsson A., Jørgensen K. J., et al. Discrepancies in sample size calculations and data analyses reported in randomised trials: comparison of publications with protocols. BMJ. 2008; 337: a2299.

31. Jack A. European drugs watchdog to step up scrutiny. Financial Times. 2012 March 6.

32. Hillaire-Buys D., Faillie J. L., Montastruc J. L. Pioglitazone and bladder cancer. Lancet. 2011; 378: 1543–4.

33. European Medicines Agency. Assessment report, Pioglitazone ratio. EMA/391408/2012. 2012 May 24.

34. Ray W. A., Stein C. M. Reform of drug regulation – beyond an independent drug-safety board. N Engl J Med. 2006; 354: 194–201.

35. Hillaire-Buys D., Faillie J. L. Pioglitazone and the risk of bladder cancer. BMJ. 2012; 344: e3500.

36. FDA Drug Safety Communication. Update to Ongoing Safety Review of Actos (pioglitazone) and Increased Risk of Bladder Cancer. 2011 June 6.

37. Kassirer J. P. On the Take: how medicine’s complicity with big business can endanger your health. Oxford: Oxford University Press; 2005.

38. Avorn J. Powerful Medicines: the benefi ts, risks, and costs of prescription drugs. New York: Vintage Books; 2005.

39. Brody H. Hooked: ethics, the medical profession, and the pharmaceutical industry. Lanham: Rowman & Littlefi eld; 2008.

40. Nissen S. E., Wolski K., Topol E. J. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA. 2005; 294: 2581–6.

41. Brophy J. M. Selling safety – lessons from muraglitazar. JAMA. 2005; 294: 2633–5.

42. Abramson J. Overdo$ed America. New York: HarperCollins; 2004.

43. Saenz A., Fernandez-Esteban I., Mataix A., et al. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2005; 3: CD002966.

44. Wikipedia. Metformin. Available online at: http://en.wikipedia.org/wiki/Metformin (accessed 12 October 2012).

45. Spranger J., Gundert-Remy U., Stammschulte T. GLP-1-based therapies: the dilemma of uncertainty. Gastroenterology. 2011; 141: 20–3.

46. Elashoff M., Matveyenko A. V., Gier B., et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011; 141: 150–6.

47. Gøtzsche P. C., Mæhlen J., Zahl P. H. What is publication? Lancet. 2006; 368: 1854–6.

48. Public citizen to FDA: pull diabetes drug Victoza from market immediately. Public Citizen. 2012 April 19.

49. Lindeberg M. [Novo Nordisk has sent warnings about the cancer risk with its diabetes drug Victoza to US physicians]. Berlingske. 2011 June 14.

50. US Food and Drug Administration. FDA Approves New Treatment for Type 2 Diabetes. 2010 Jan 25.

51. Maxmen A. Debate on diabetes drugs gathers pace: petition unveils unnerving reports on potential carcinogenicity of GLP-1 mimics. Nature. 2012 April 30.

16. Психиатрия – рай для фармацевтической промышленности